BioPharmSignal logoBioPharmSignal

Biotech News

Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting

Theravance Biopharma (TBPH)Theravance BiopharmaClinical readout

A retrospective cohort study of claims data demonstrated that following hospital discharge, patients adherent to YUPELRI experienced significantly fewer, and less severe, exacerbations and had significantly lower healthcare costs than non-adherent patients Post-hoc analyses of a Phase 3 safety

Related news

TBPHTheravance Biopharma2025-10-29 10:00 EST

Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System

TBPHTheravance Biopharma2026-03-03 13:30 EST

Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions

RVPHReviva Pharmaceuticals2025-10-28 12:00 EST

Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025

XAIRBeyond Air2026-04-20 12:00 EST

Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026

XAIRBeyond Air2026-02-04 13:00 EST

Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026

RVPHReviva Pharmaceuticals2025-11-12 13:00 EST

Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025

VERUVeru Inc2026-09-08 12:17 EST

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial

VERUVeru Inc2026-08-10 10:30 EST

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

INSMInsmed2026-03-23 11:00 EST

Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease

INSMInsmed2026-09-03 11:00 EST

Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026

View all latest news

Theravance Biopharma

Respiratory Medicines Theravance Biopharma is a biopharmaceutical company whose principal economic asset is a respiratory medicine commercialized through a collaboration. YUPELRI YUPELRI, or revefenacin, is a once-daily nebulized long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease....

Recent company news

TBPHTheravance Biopharma2026-08-10 12:30 EST

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

TBPHTheravance Biopharma2026-06-29 10:00 EST

THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT

TBPHTheravance Biopharma2026-05-07 12:30 EST

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

TBPHTheravance Biopharma2026-03-19 12:30 EST

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

TBPHTheravance Biopharma2026-03-03 13:30 EST

Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions

Stock data

Close
17.03 USD
Market cap
803.2M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States